Buy Rating for Evaxion Biotech Supported by Strong Clinical Results and PIONEER Platform’s Potential
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Evaxion Biotech (EVAX – Research Report) today and set a price ...
pharmaphorum2d
Job losses loom at Achilles as TIL therapy platform is cut
Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...
Vaccine experts report positive results on Phase 1 trial of personalized vaccine for lymphoplasmacytic lymphoma
A team of researchers from City of Hope and The University of Texas M.D. Anderson Cancer Center has reported safety and ...
City of Hope Vaccine Experts Report Positive Results on Phase 1 Trial of Personalized Vaccine for Lymphoplasmacytic Lymphoma
A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in ...
Armed robbery in Revesby2d
Hope Vaccine Experts Positive on Lymphoma Trial
A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S ...
Achilles Therapeutics Announces Strategic Update
Achilles to discontinue development of TIL-based cNeT therapy––Cash position of $95.1 million as of June 30, 2024––BofA Securities engaged to ...
The American Journal of Managed Care3d
Can Vaccines Be Developed for MPNs? Study Examines the Challenges
Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for ...
AZoRobotics on MSN4d
Evaxion Biotech Reports Positive One-Year Results for AI-Designed Cancer Vaccine
Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces ...
TMCnet5d
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
In the completed Phase 1/2a clinical trial (NCT03715985), assessing EVX-01 in combination with a PD-1 inhibitor, eight of twelve metastatic melanoma patients (67%) had objective clinical responses ...
The Brighterside of News on MSN6d
First-ever mRNA vaccine halts pancreatic cancer in its tracks
RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the third tranche ...